8-K: Pasithea Therapeutics Corp. Annual Meeting Approves Key Proposals

Pasithea Therapeutics Corp. announced the approval of director elections, auditor ratification, and a reverse stock split authorization at its September 9, 2026 Annual Meeting.

Summary

• Pasithea Therapeutics Corp. held its Annual Meeting on September 9, 2026, where shareholders voted on three key proposals.
• The proposals included the election of two Class III directors, the ratification of CBIZ CPAs P.C. as the independent auditor for fiscal year 2026, and the approval of an amendment to the Certificate of Incorporation to effect a reverse stock split.
• A quorum was established with 26,142,328 shares represented out of 33,414,448 outstanding shares.
• Dr. Tiago Reis Marques and Prof. Lawrence Steinman were elected as Class III directors.
• CBIZ CPAs P.C. was ratified as the independent auditor for the fiscal year ending December 31, 2026.
• Shareholders approved an amendment allowing the Board of Directors to implement a reverse stock split, with ratios ranging from 1-for-2 to 1-for-20, at their discretion, within one year of the meeting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as key proposals were approved, including a reverse stock split which can be a precursor to uplisting or attracting institutional investors, though the necessity of such a split may indicate underlying share price weakness.

Positives

• The election of directors and ratification of the independent auditor were approved, ensuring continuity in leadership and financial oversight.
• Shareholder approval for a reverse stock split provides the company with strategic flexibility to potentially improve its stock price and meet exchange listing requirements.
• A quorum was met, indicating sufficient shareholder participation and engagement in the meeting's proceedings.

Negatives

• The need for a reverse stock split, with a potential ratio of up to 1-for-20, suggests that the company's common stock has experienced significant price depreciation, potentially impacting investor confidence.
• A substantial number of broker non-votes were recorded for the director elections, indicating a lack of active participation or direction from some beneficial owners.

Risks

• The authorization for a reverse stock split carries the risk of not achieving its intended objectives, such as improving stock price or attracting institutional investment, and could be perceived negatively by the market.
• The Board of Directors has broad discretion in determining the reverse stock split ratio, which could lead to uncertainty for shareholders regarding the exact impact on their holdings.

Future Outlook

The company has authorized its Board of Directors to implement a reverse stock split at a ratio between 1-for-2 and 1-for-20, at any time prior to the one-year anniversary of the Annual Meeting, with the exact ratio to be determined by the Board.

Management Comments

• The Board of Directors of the Company (the Board), to effect a reverse stock split of the Companys issued shares of Common Stock, at a specific ratio, ranging from one-for-two (1:2) to one-for-twenty (1:20), at any time prior to the one-year anniversary date of the Annual Meeting, with the exact ratio to be determined by the Board without further approval or authorization of the Companys stockholders.

Industry Context

StockSavvy.ai notes that reverse stock splits are often employed by companies facing delisting threats or seeking to appear more attractive to institutional investors. This action by Pasithea Therapeutics Corp. suggests a strategic move to address its current market valuation and potentially improve its standing on exchanges like Nasdaq.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares held, with a corresponding increase in the per-share price, if the reverse stock split is enacted.
• The election of new directors ensures continued board oversight and strategic direction.
• The ratification of the auditor provides assurance regarding the integrity of the company's financial reporting.

Next Steps

• The Board of Directors will determine the specific ratio for the reverse stock split.
• The reverse stock split will be implemented at a ratio ranging from 1-for-2 to 1-for-20.
• The reverse stock split must be implemented prior to the one-year anniversary of the Annual Meeting (September 9, 2027).

Key Dates

Recommendation

The approval of a reverse stock split is a neutral to slightly positive event, providing strategic flexibility but also signaling potential underlying share price weakness. The election of directors and auditor ratification are standard governance procedures. Without further financial performance data or strategic clarity, a 'hold' recommendation is prudent, allowing investors to observe the impact of the reverse split and future company performance.

Keywords

Annual Meeting, Reverse Stock Split, Director Election, Independent Auditor, Corporate Governance, Shareholder Vote, Certificate of Incorporation